Health Canada

In 2016, Health Canada reviewed the risk of gadolinium build-up in the brain and the unknown potential neurological side effects because some published studies showed that gadolinium may stay in the brain when GBCAs are given repeatedly. Health Canada’s review concluded that the risk of gadolinium build-up in the brain is higher with repeated doses of both types of GBCAs, and with the use of linear GBCAs compared to macrocyclic GBCAs; however, no neurological side effects were found in either of these situations. The product information for all GBCAs was updated in June 2017 to include warnings about the potential for gadolinium build-up in the brain, and advice to use the lowest dose needed and to carefully consider whether repeated doses are required.

Image: sciencemission.com